AlzeCure Pharma Total Liabilities

Latest as of September 2025: Skr15.93 Million SEK ≈ $1.71 Million USD

AlzeCure Pharma total liabilities. Based on the latest financial reports, AlzeCure Pharma (ALZCUR) has total liabilities worth Skr15.93 Million SEK (≈ $1.71 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See AlzeCure Pharma defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Total Liabilities of AlzeCure Pharma (2017–2024)

Total liabilities of AlzeCure Pharma from 2017 to 2024. This chart illustrates how AlzeCure Pharma's total liabilities have evolved over time, based on quarterly financial data.

AlzeCure Pharma Competitors by Total Liabilities

The table below lists competitors of AlzeCure Pharma ranked by their total liabilities.

Company	Country	Total Liabilities
Ribbon Acquisition Corp Unit NASDAQ:RIBBU	USA	$2.61 Million
Daehan Green Power Corporation KQ:060900	Korea	₩11.26 Billion
Velan Inc. TO:VLN	Canada	CA$150.39 Million
Everest Industries Limited NSE:EVERESTIND	India	Rs7.16 Billion
KCC Engineering & Construction Co. Ltd KQ:021320	Korea	₩877.17 Billion
Brompton Lifeco Split Corp TO:LCS	Canada	CA$87.62 Million
SUI Group Holdings Limited NASDAQ:SUIG	USA	$14.11 Million
Clipan Finance Indonesia Tbk JK:CFIN	Indonesia	Rp4.04 Trillion

Liability Composition Analysis (2017–2024)

This chart breaks down AlzeCure Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of AlzeCure Pharma.

Liquidity & Leverage Metrics

AlzeCure Pharma Total Liabilities Ratios Explained

AlzeCure Pharma total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	4.75	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.31	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how AlzeCure Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for AlzeCure Pharma (2017–2024)

The table below shows the annual total liabilities of AlzeCure Pharma from 2017 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr8.25 Million ≈ $887.83K	+0.28%
2023-12-31	Skr8.23 Million ≈ $885.36K	-20.54%
2022-12-31	Skr10.35 Million ≈ $1.11 Million	-18.30%
2021-12-31	Skr12.67 Million ≈ $1.36 Million	+79.20%
2020-12-31	Skr7.07 Million ≈ $761.06K	+48.95%
2019-12-31	Skr4.75 Million ≈ $510.96K	+2.93%
2018-12-31	Skr4.61 Million ≈ $496.43K	+11.26%
2017-12-31	Skr4.15 Million ≈ $446.18K	--

About AlzeCure Pharma

ST:ALZCUR Sweden Biotechnology

Market Cap

$76.18 Million

Skr707.87 Million SEK

Market Cap Rank

#20067 Global

#354 in Sweden

Share Price

Skr6.16

Change (1 day)

-3.14%

52-Week Range

Skr1.34 - Skr8.44

All Time High

Skr11.60